Dr. Mimi Roy

BioMarin Pharmaceutical Inc.

How Mass Spectrometry is Accelerating Rare Disease Research

Mimi Roy, Senior Director of Analytical Chemistry, BioMarin Pharmaceutical Inc., explores the impact of mass spectrometry on medical research, right from drug discovery to compound characterization, through drug manufacturing. The superior precision of the latest mass spectrometry technology has enabled the team at BioMarin to accelerate research into rare diseases such phenylketonuria, mucopolysaccharidosis, or haemophilia.

LIKE 4


Dr. Mimi Roy
Biopharma

Dr. Mimi Roy

Biography

Senior Director, BioMarin Pharmaceutical Inc. More
Follow Mimi

Dr. Mimi Roy

BioMarin Pharmaceutical Inc.

Mimi Roy is Senior Director, Analytical Chemistry at BioMarin since November 2015. Her primary interests are scientific management and drug development (protein engineering, CMC and translation sciences) with a focus on protein characterization, high-end molecular analytics including mass spectrometry and NMR. In 2014 she founded iON Bioservices, an analytical services & consulting firm, and co-founded SensiBrace Technologies - obtaining a patent on a device to address carpal tunnel syndrome, a condition she suffers from. Previously she served as the US Site-Head of Caprion Inc. with oversight of science and sales, and as Director of Analytics at Sutro Biopharma. Mimi has a B.Sc. (Honours) from St. Stephens College, New Delhi and a M.S. from University of Sydney in Biochemistry. She completed a Ph.D. in Chemistry from Princeton University in 1998 specializing in Protein Design and Characterization, followed by a post-doctoral fellowship in DNA Design with Peter Schultz, Professor, CEO & President, The Scripps Research Institute, La Jolla. Mimi lives in San Rafael, California, and likes to spend her spare time with her family, practice yoga and sing.